emerg
spread
antimicrobialresist
bacteri
viral
fungal
pathogen
diminish
treatment
option
avail
major
global
concern
new
viral
respiratori
tract
infect
epidem
potenti
sever
acut
respiratori
syndrom
swineorigin
infl
uenza
middl
east
respiratori
syndrom
coronaviru
infect
requir
develop
new
antivir
agent
substanti
rise
global
number
patient
respiratori
tract
infect
caus
panantibioticresist
gramposit
gramneg
bacteria
multidrugresist
mycobacterium
tuberculosi
multiazoleresist
fungi
focus
attent
invest
develop
new
drug
treatment
regimen
success
treatment
outcom
patient
respiratori
tract
infect
across
healthcar
set
necessit
rapid
precis
diagnosi
eff
ectiv
pathogenspecifi
c
therapi
seri
paper
describ
develop
use
new
antimicrobi
agent
immunebas
hostdirect
therapi
rang
convent
emerg
viral
bacteri
fungal
caus
respiratori
tract
infect
emerg
diffi
culttotreat
known
novel
bacteri
viral
fungal
respiratori
tract
pathogen
epidem
potenti
major
global
concern
treatment
option
limit
increas
antimicrobialdrug
resist
howev
new
viral
infect
caus
sever
respiratori
tract
diseas
pandem
potenti
focus
global
attent
substanti
rise
number
patient
multidrugresist
pulmonari
tuberculosi
pandrugresist
bacteria
note
increas
use
immunosuppress
agent
broadspectrum
antibiot
anticanc
agent
coupl
resist
azol
led
increas
number
invas
pulmonari
fungal
infect
result
high
morbid
mortal
success
treatment
outcom
patient
respiratori
tract
infect
across
healthcar
set
requir
appropri
eff
ectiv
pathogenspecifi
c
drug
altern
treatment
describ
rang
convent
emerg
viral
bacteri
fungal
caus
respiratori
tract
infect
new
antimicrobi
drug
immunebas
hostdirect
therapi
develop
studi
outbreak
sever
acut
respiratori
syndrom
coronaviru
sarscov
reemerg
avian
infl
uenza
global
circul
oseltamivirresist
season
infl
uenza
subsequ
emerg
pandem
infl
uenza
strain
viru
continu
circul
shown
potenti
limit
current
antivir
treatment
sever
respiratori
viral
infect
epidem
wave
avian
infl
uenza
sporad
case
avian
infl
uenza
ongo
outbreak
middl
east
respiratori
syndrom
coronaviru
merscov
infect
burden
common
respiratori
virus
season
infl
uenza
respiratori
syncyti
viru
rhinovirus
adenovirusesshow
develop
eff
ectiv
therapi
reduc
morbid
mortal
urgent
need
research
focus
repurpos
avail
antivir
drug
gener
specifi
c
use
two
class
antivir
drug
approv
prevent
treatment
infl
uenza
countri
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
peramivir
zanamivir
laninamivir
tabl
gener
antivir
treatment
indic
earli
possibl
patient
confi
rmed
suspect
infl
uenza
sever
complic
progress
ill
admit
hospit
outpati
higher
risk
infl
uenza
complic
time
treatment
onset
symptom
ill
sever
extent
viral
replic
key
variabl
respect
respons
start
treatment
delay
diagnost
test
inhibitorsalso
known
adamantanesar
ineff
ectiv
infl
uenza
b
virus
recent
circul
infl
uenza
pandem
infl
uenza
virus
resist
mutat
ion
channel
howev
proport
avian
infl
uenza
strain
suscept
combin
use
adamantan
neuraminidas
inhibitor
improv
antivir
activ
suscept
isol
two
neuraminidas
inhibitor
approv
use
countri
oseltamivir
zanamivir
laninamivir
approv
use
japan
peramivir
china
japan
south
korea
sever
observ
studi
shown
adult
admit
hospit
sever
infl
uenza
given
oseltamivir
mortal
fall
clinic
outcom
improv
especi
treatment
initi
within
day
onset
symptom
posit
eff
ect
note
begun
late
day
onset
oseltamivir
reduc
mortal
infl
uenza
infect
given
onset
respiratori
failur
might
benefi
cial
start
late
day
symptom
onset
patient
admit
hospit
sever
infl
uenza
infect
reduct
viral
load
treatment
oseltamivir
correl
improv
outcom
wherea
emerg
viru
resist
neuraminidas
inhibitor
harbour
substitut
associ
poor
outcom
poor
respons
oseltamivir
peramivir
standard
durat
oseltamivir
treatment
day
longer
treatment
recommend
critic
ill
patient
respiratori
failur
often
prolong
viral
replic
lower
respiratori
tract
despit
treatment
whether
increas
dose
provid
greater
antivir
eff
ect
patient
investig
randomis
control
trial
patient
hospit
children
show
virolog
clinic
advantag
doubl
dose
oseltamivir
given
rather
standard
dose
addit
benefi
note
highdos
oseltamivir
adult
admit
infl
uenza
although
faster
virolog
respons
note
infl
uenza
b
howev
randomis
control
trial
critic
ill
patient
pandem
infl
uenza
tripledos
oseltamivir
regimen
associ
signifi
cantli
higher
proport
viral
clearanc
day
standard
therapi
vs
studi
intraven
neuraminidas
inhibitor
underway
provid
data
valu
highdos
therapi
zanamivir
laninamivir
gener
similar
profi
le
suscept
exampl
mutat
confer
highlevel
resist
oseltamivir
carboxyl
reduc
suscept
peramivir
virus
substanti
diminish
suscept
zanamivir
laninamivir
inhal
zanamivir
studi
detail
sever
ill
patient
admit
hospit
eff
ectiv
deliveri
site
viral
replic
toler
could
issu
contrast
intraven
zanamivir
use
wide
compassion
basi
sinc
pandem
particularli
late
treatment
critic
ill
adult
pandem
infl
uenza
viru
infect
suspect
proven
oseltamivir
resist
one
trial
shown
drugrel
trend
safeti
measur
subset
patient
posit
baselin
infl
uenza
show
median
decreas
nasopharyng
viral
rna
load
log
copi
per
ml
day
treatment
phase
trial
patient
admit
hospit
underway
phase
randomis
control
trial
inhal
laninamivir
uncompl
infl
uenza
fail
show
superior
ill
allevi
primari
endpoint
compar
placebo
trial
involv
patient
test
mg
mg
dose
inhal
drug
median
time
allevi
fl
u
symptom
h
mg
dose
h
mg
dose
compar
h
placebo
hostdirect
receptordestroy
action
inhibitori
parainfl
uenza
infl
uenza
virus
includ
resist
amino
adamantan
neuraminidas
inhibitor
deliv
topic
eff
ectiv
anim
model
lethal
infl
uenza
caus
virus
includ
neuraminidaseinhibitorresist
contain
variant
phase
randomis
control
trial
inhal
reduc
pharyng
viral
replic
uncompl
infl
uenza
reduc
nasal
viral
load
improv
clinic
outcom
case
report
suggest
inhal
nebulis
might
eff
ectiv
immunocompromis
host
sever
parainfl
uenza
lung
diseas
favipiravir
activ
infl
uenza
b
c
virus
includ
strain
resist
approv
antivir
broad
rang
rna
virus
given
seri
somewhat
higher
concentr
combin
favipiravir
neuraminidas
inhibitor
addit
synergist
eff
ect
preclin
model
clinic
trial
restrict
uncompl
infl
uenza
far
clinic
trial
combin
amantadin
ribavirin
oseltamivir
vs
oseltamivir
mono
therapi
nitazoxanid
vs
oseltamivir
vs
combin
vs
placebo
favipiravir
vs
placebo
randomis
control
trial
outpati
publish
suggest
favipiravir
antivir
eff
ect
similar
oseltamivir
randomis
control
trial
show
favipiravir
shorten
time
allevi
infl
uenza
symptom
hour
compar
placebo
studi
underway
nitazoxanid
oral
antiparasit
drug
immunomodulatori
eff
ect
includ
upregul
interferon
variou
interferoninduc
gene
specifi
c
infl
uenzainhibitori
eff
ect
relat
blockad
haemagglutinin
matur
nitazoxanid
inhibit
infl
uenza
replic
vitro
phase
randomis
control
trial
signifi
cant
antivir
eff
ect
log
reduct
nasal
viral
load
result
signifi
cantli
faster
time
allevi
ill
roughli
h
diff
erenc
median
placebo
uncompl
infl
uenza
placebocontrol
randomis
trial
nitazoxanid
versu
oseltamivirand
com
binat
thereofin
uncompl
infl
uenza
hospitalbas
studi
use
sever
respiratori
ill
progress
nonrandomli
assign
studi
case
report
suggest
convalesc
plasma
neutralis
antibodi
use
addon
therapi
patient
sar
sever
infl
uenza
pneumonia
includ
caus
infl
uenza
recent
publish
systemat
review
avail
sar
infl
uenza
treatment
studi
employ
convalesc
plasma
serum
found
signifi
cant
overal
mortal
benefi
prospect
observ
studi
show
lower
crude
mortal
faster
nasopharyng
viral
clearanc
plasmatr
patient
admit
sever
pandem
infl
uenza
infect
wherea
randomis
control
trial
reduct
mortal
report
sever
ill
hyperimmun
globulin
given
within
day
onset
symptom
tabl
heterosubtyp
haemagglutinin
stemneutralis
antibodi
highli
eff
ectiv
anim
enter
clinic
evalu
human
be
combin
antivir
diff
erent
mechan
action
eg
neuraminidas
inhibitor
polymeras
inhibitor
favipiravir
broadspectrum
antihaemagglutininneutralis
antibodi
oral
rimantadin
nebulis
salin
posthoc
analysi
show
faster
cough
resolut
signifi
cant
diff
erenc
proport
patient
shed
viru
treatment
day
zanamivir
plu
rimantadin
placebo
plu
rimantadin
durat
hospitalis
supplement
oxygen
use
underpow
low
enrol
oseltamivir
corticosteroid
rapid
improv
partial
pressur
oxygen
fraction
inspir
oxygen
sequenti
organ
failur
assess
score
shorter
ventil
use
median
day
vs
day
faster
viral
clearanc
sirolimu
control
group
rctrandomis
control
trial
retrospect
studi
critic
ill
adult
mortal
rate
diff
er
receiv
tripl
combin
antivir
drug
receiv
oseltamivir
randomis
control
trial
sponsor
nation
institut
allergi
infecti
diseas
higherrisk
outpati
underway
hostdirect
therapi
aim
reduc
damag
consequ
host
immun
respons
pathogen
combin
antivir
hostdirect
therapi
immunomodul
sirolimu
mtor
inhibitor
block
host
pathway
need
viral
replic
tabl
might
also
enhanc
antivir
activ
hostdirect
therapi
inhibit
cellular
target
need
effi
cient
viral
replic
eg
rafmekerk
mitogen
kinas
cascad
modul
might
provid
futur
option
clinic
test
role
adjunct
immunomodulatori
therapi
sever
infl
uenza
respiratori
viral
infect
remain
uncertain
sever
observ
studi
show
system
corticosteroid
given
pandem
infl
uenza
viral
pneumonia
increas
risk
mortal
morbid
eg
secondari
infect
especi
delay
initi
absenc
eff
ectiv
antivir
therapi
use
might
delay
viral
clearanc
increas
risk
emerg
resist
fungal
infect
potenti
adjunct
therapi
infl
uenza
includ
intraven
immunoglobulin
nacetylcystein
statin
macrolid
peroxisom
proliferatoractiv
receptor
agonist
celecoxib
mesalazin
plasmapheresi
haemo
perfus
chloroquin
eff
ectiv
infl
uenza
infect
one
anim
model
ineff
ectiv
anim
model
one
human
randomis
control
trial
interferon
merscov
infect
caus
sever
respiratori
diseas
higher
mortal
medic
comorbid
although
empir
treatment
rang
antivir
tri
sever
respiratori
tract
infect
caus
merscov
sarscov
regimen
rigor
assess
clinic
trial
panel
merscov
elicit
attenu
innat
immun
respons
delay
proinfl
ammatori
cytokin
induct
cell
cultur
vivo
also
readili
inhibit
type
interferon
interferon
alfa
especi
interferon
beta
suggest
potenti
therapeut
use
interferon
earli
pegyl
interferon
alfa
therapi
eff
ectiv
sar
primat
model
treatment
plu
system
corticosteroid
associ
improv
oxygen
satur
rapid
resolut
radiograph
lung
opac
system
corticosteroid
alon
uncontrol
studi
patient
sar
patient
studi
interferon
merscov
seem
warrant
ribavirin
use
extens
patient
sar
without
benefi
cial
eff
ect
complic
haemolyt
anaemia
metabol
disturb
mani
case
combin
interferon
alfa
ribavirin
reduc
lung
injuri
moder
decreas
viral
replic
log
reduct
lung
titr
given
rhesu
macaqu
within
h
inocul
merscov
treatment
combin
given
sever
sever
ill
patient
mer
infect
prove
fatal
probabl
late
administr
advanc
stage
diseas
ribavirin
invitro
inhibitori
eff
ect
merscov
use
proteas
inhibitor
lopinavir
ritonavir
initi
therapi
sar
associ
signifi
cantli
less
death
vs
p
intub
vs
p
use
ribavirin
alon
match
histor
cohort
lopinavir
ritonavir
intial
treatment
vs
match
histor
cohort
howev
one
studi
report
nelfi
navir
lopinavir
high
eff
ectiv
inhibitori
concentr
ec
merscov
vitro
wherea
anoth
found
inhibit
lopinavir
clinic
achiev
concentr
sever
drug
shown
inhibitori
eff
ect
merscov
cell
cultur
includ
interferon
ciclosporin
mycophenol
acid
mycophenol
acid
inhibitori
clinic
achiev
concentr
combin
mycophenol
acid
interferon
lower
ec
drug
onetothre
time
dipeptidyl
peptidas
also
known
function
receptor
merscov
polyclon
antibodi
show
invitro
inhibitori
eff
ect
merscov
contrast
inhibitor
enzymat
action
eg
gliptin
inhibit
viral
replic
time
administr
neutralis
antibodi
could
high
likelihood
therapeut
success
treatment
convalesc
plasma
patient
recov
sarscov
infect
contain
high
level
neutralis
antibodi
within
week
ill
onset
result
higher
proport
discharg
day
treatment
day
onset
vs
p
show
wors
outcom
system
corticosteroid
given
sar
consequ
use
avoid
unless
care
control
prospect
studi
done
test
eff
ectiv
combin
antivir
sever
observ
studi
shown
system
corticosteroid
given
pandem
infl
uenza
viral
pneumonia
acut
respiratori
distress
syndrom
increas
risk
mortal
morbid
eg
secondari
bacteri
fungal
infect
especi
delay
lack
eff
ectiv
antivir
therapi
use
system
corticosteroid
probabl
contribut
delay
viral
clearanc
emerg
antivir
resist
patient
sever
infl
uenza
infect
requir
extracorpor
membran
oxi
genat
infl
uenza
increas
risk
invas
aspergillosi
especi
among
immunocompromis
patient
often
silent
infect
earli
stage
direct
surveil
aspergillu
antigen
pcr
test
respiratori
secret
advis
patient
treat
fungal
infect
undergo
antifung
therapeut
drug
monitor
data
insuffi
cient
support
routin
use
immun
therapi
better
anim
data
care
systemat
clinic
studi
includ
serial
virolog
measur
prioriti
treatment
convalesc
plasma
interferon
randomis
control
trial
case
number
suffi
cient
need
current
clinic
manag
patient
sever
respiratori
tract
infect
due
merscov
larg
reli
meticul
intens
care
support
treatment
prevent
complic
research
done
patient
haemopoiet
stemcel
transplant
show
adopt
transfer
antigenspecifi
c
cell
restor
protect
immun
prevent
revers
diseas
due
opportunist
viral
infect
cytomegaloviru
transplant
recipi
transfer
donorderiv
cell
result
resolut
infect
expans
virusspecifi
c
cell
associ
clinic
improv
transfer
donor
cell
associ
risk
sever
acut
graftversushost
diseas
thu
tcell
therapi
done
patient
low
lymphocyt
count
lymphopenia
enabl
low
number
cell
transfer
prolifer
lymphopen
host
like
result
interleukin
patient
receiv
immunosuppress
treatment
tcell
therapi
tcell
therapi
target
cytomegaloviru
strain
resist
drug
treatment
clinic
relev
lung
transplant
recipi
tcell
expans
requir
time
induc
clinic
regress
viral
infect
sever
approach
might
applic
situat
necessit
fast
clinic
actioneg
use
synthet
mhc
antigen
load
relev
peptid
pathogen
interest
socal
tetram
multim
mhcpeptid
complex
engag
pathogenspecifi
c
lymphocyt
express
pathogenspecifi
c
tcell
receptor
pathogenspecifi
c
cell
isol
use
solubl
mhcpeptid
complex
immedi
transfer
patient
salvag
treatment
viral
infect
tcell
expans
also
achiev
sever
stimuli
target
sever
infecti
pathogen
expans
cell
target
sever
antigen
cytomegaloviru
epsteinbarr
viru
adenoviru
provid
broad
antivir
specifi
citi
stemcel
transplant
altern
approach
seri
becom
independ
exvivo
expans
cell
identifi
cation
tcell
receptor
would
recognis
viral
infect
cell
could
transfer
recipi
eff
ector
cell
cell
also
engin
produc
antivir
rna
would
block
viral
infect
synthet
antisens
molecul
phosphorodiamid
morpholino
oligom
structur
similar
rna
phosphorodiest
linkag
replac
neutral
phosphorodiamid
linkag
ribos
ring
sixmemb
morpho
lino
ring
chang
gene
express
inhibit
translat
disrupt
rna
secondari
structur
interf
premrna
splice
use
phosphorodiamid
morpho
lino
oligom
coupl
argininerich
cellpenetr
peptid
repeatedli
demonstr
bacteri
pathogen
could
viabl
option
microbi
gene
interest
specifi
c
biolog
therapi
infecti
pathogen
target
drugresist
pathogen
also
immun
evas
mechan
antibodi
direct
bcell
marker
fuse
tcell
signal
molecul
express
cell
could
kill
target
cell
encount
nomin
target
antigen
chimericantigenreceptor
cell
use
remov
epsteinbarrvirusposit
lymphoma
cell
case
posttransplant
prolif
diseas
similar
approach
use
eff
ectiv
remov
pathogeninfect
cell
specifi
c
antibodi
exist
target
molecul
express
infect
cell
frequenc
spectrum
resist
antibiot
specifi
c
bacteri
pathogen
caus
respiratori
tract
infect
continu
increas
worryingli
multidrugresist
streptococcu
pneumoniaewith
resist
three
antibioticswa
initi
note
south
africa
subsequ
mani
countri
alarm
rate
pneumonia
multidrug
resist
usa
spain
european
antimicrobi
resist
surveil
system
show
pneumonia
intermedi
penicillin
suscept
penicillin
resist
resist
erythromycin
concern
multidrugresist
panantibioticresist
gramneg
bacteria
focus
klebsiella
pneumonia
enterobact
spp
product
extend
spectrum
lactamas
klebsiella
pneumonia
carba
penemas
ampc
acinetobact
baumannii
pseudomona
aeruginosa
one
survey
us
health
centr
gramneg
bacteria
resist
antibiot
except
colistin
acinetobact
spp
pseudomona
spp
enterobact
spp
resist
therapeut
option
treat
infect
limit
carbapenem
recommend
organ
produc
extendedspectrum
lactamas
metaanalysi
doripenem
eff
ectiv
p
aeruginosa
infect
compar
modifi
ed
intentiontotreat
analys
polymyxin
b
colistin
concentrationdepend
bactericid
agent
bind
bacteri
cell
membran
reliabl
activ
acinetobact
spp
novel
inhibitor
antibiot
com
binat
therapi
might
provid
stopgap
measur
fulfi
lling
clinic
need
antibiot
develop
pipelin
remain
thin
global
attent
focus
increas
awar
invest
develop
new
antibacteri
agent
antibacteri
innov
coupl
rais
global
awar
prudent
use
avail
drug
estim
million
peopl
die
worldwid
tuberculosi
multidrugresist
diseas
multidrugresist
tuberculosi
caus
mycobacterium
tuberculosi
bacilli
resist
least
isoniazid
rifampicin
widespread
global
estim
half
million
case
extens
drugresist
tuberculosisresist
rifampicin
isoniazid
fl
uoroquinolon
least
one
three
inject
secondlin
drug
amikacin
kanamycin
capreomycinha
report
countri
recommend
use
secondlin
drug
month
longer
extens
drugresist
multidrugresist
diseas
treatment
success
rate
low
individualis
standard
regimen
new
drug
regimen
need
past
year
promis
pipelin
new
drug
treatment
multidrugresist
extens
drugresist
tuberculosi
emerg
progress
made
repurpos
drug
alreadi
avail
includ
reengin
exist
antibacteri
compound
redesign
scaff
old
lead
discoveri
new
compound
two
new
drug
delamanid
bedaquilin
approv
regulatori
author
new
drug
combin
older
drug
treat
multidrugresist
diseas
hostdirect
adjunct
therapi
sever
approach
ration
develop
adjunct
immunebas
therapi
multidrugresist
tuberculosi
develop
nonsteroid
antiinfl
ammatori
drug
reduc
tuberculosi
load
seri
allevi
lung
diseas
mice
effl
ux
pump
inhibitor
verapamil
reserpin
reduc
macrophageinduc
drug
toler
thu
could
use
adjunct
hostdirect
therapi
phosphodiesteras
inhibitor
cilostazol
sildenafi
l
improv
mycobacteri
clearanc
decreas
time
sterilis
reduc
tissu
infl
ammat
rang
adjunct
immunotherapi
approach
implic
cytokin
inhibitor
biolog
immunomodulatori
compound
assess
mean
limit
damag
infl
ammatori
respons
tuberculosi
variou
cytokin
regimen
includ
interferon
c
interleukin
assess
variabl
eff
ect
antiinfl
ammatori
eff
ect
macrolid
antibiot
need
studi
whole
genom
sequenc
might
allow
rapid
determin
resist
pattern
tuberculosi
strain
enabl
tailor
treatment
regimen
immunomodulatori
strategi
includ
restor
eff
ectiv
antipathogendirect
immunoresponsesand
consequ
decreas
damag
host
respons
lung
tissuesin
multidrugresist
tuberculosi
infus
patient
bonemarrowderiv
stromal
cell
phase
trial
show
procedur
safe
phase
trial
plan
assess
eff
ect
mesenchym
stromal
cell
adjunct
therapi
clinic
microbiolog
outcom
invas
fungal
respiratori
tract
infect
increasingli
report
worldwid
tabl
two
common
pulmonari
fungal
pathogen
aspergillu
fumigatu
pneumocysti
jirovecii
increasingli
repres
primari
caus
morbid
mortal
critic
ill
patient
across
europ
africa
asia
result
peopl
live
hiv
increas
use
immunomodulatori
drug
patient
cancer
transplant
use
broadspectrum
antibiot
patient
relaps
micro
biolog
unconfi
rmed
multidrugresist
tuber
culosi
altern
diagnos
includ
chronic
pulmonari
aspergillosi
com
prehens
search
altern
fungal
diagnos
smear
cultur
neg
case
done
patient
multidrugresist
diseas
aspergillu
import
fungal
caus
invas
pulmonari
diseas
fumigatu
caus
case
voriconazol
eff
ectiv
treatment
invas
aspergillosi
resist
note
contin
except
south
america
widespread
use
azol
fungicid
agricultur
led
environment
develop
panazol
resist
resist
also
emerg
treatment
typic
itraconazol
possibl
link
combin
low
blood
concentr
drug
high
fungal
load
model
suggest
million
peopl
sever
asthma
fungal
sensitis
much
adult
asthma
attend
secondari
care
fungal
sensitis
estim
million
adult
allerg
bronchopulmonari
aspergillosi
peopl
asthma
sensitis
fumigatu
much
higher
rate
bronchiectasi
unsensitis
reclassifi
cation
aspergillosi
adult
cystic
fi
brosi
aspergillu
serolog
ige
igg
pcr
antigen
sputum
show
three
distinct
class
aspergillosi
allerg
bronchopulmonari
diseas
aspergillu
sensitis
aspergillu
bronchiti
remain
patient
diseas
longterm
oral
antifung
therapi
benefi
cial
patient
asthma
unproven
benefi
cystic
fi
brosi
resist
fumigatu
report
throughout
europ
roughli
sampl
patient
cystic
fi
brosi
new
fungu
caus
dissemin
infect
patient
aid
identifi
ed
molecular
identifi
cation
basi
sequenc
show
isol
new
speci
tightli
cluster
similar
emmonsia
pasteuriana
emmonsia
parva
slightli
distantli
relat
histoplasma
capsulatum
clinic
featur
infect
includ
fever
loss
weight
anaemia
skin
lesion
akin
dissemin
histoplasmosi
chest
radiograph
similar
note
pulmonari
tuberculosi
fungu
cultur
skin
blood
sputum
csf
signifi
cant
clinic
respons
note
patient
given
intraven
amphotericin
b
follow
itraconazol
larg
combin
studi
seri
reach
primari
endpoint
reduc
mortal
although
patient
posit
galactomannan
seem
benefi
guidelin
manag
invas
aspergillosi
still
favour
voriconazol
treatment
combin
therapi
usual
recommend
tablet
formul
posaconazol
bioavail
oral
suspens
avail
given
day
us
food
drug
administr
approv
intraven
suspens
drug
new
drug
approv
isavuconazol
broadspectrum
azol
avail
intraven
oral
form
applic
approv
submit
juli
itraconazol
seem
safe
fi
rst
trimest
pregnanc
wherea
fl
uconazol
increas
risk
fallot
tetralog
factor
three
one
driver
develop
new
antifung
drug
includ
inadequ
respons
rate
absenc
oral
prepar
echinocandin
drug
interact
import
drug
toxic
eff
ect
especi
amphotericin
b
voriconazol
triazol
echinocandin
resist
sever
drug
repurpos
use
antifung
new
drug
develop
tabl
sertralin
use
depress
synergist
activ
fl
uconazol
murin
model
cryptococc
infect
calcineurin
target
rapamycin
inhibitor
antifung
activ
synergsit
azol
inhibitor
initi
develop
cancer
treatment
improv
fl
uconazol
activ
vitro
anim
enoxacin
fl
uoroquinolon
antibiot
show
activ
murin
candidiasi
model
although
azol
import
treatment
invas
pulmonari
aspergillosi
degre
immunosuppress
immunolog
factor
role
treatment
outcom
antifung
immun
respons
could
improv
adapt
transfer
pathogenspecifi
c
cell
direct
invas
pulmonari
fungal
infect
particularli
infect
candida
aspergillu
mucormycet
especi
allogen
stemcel
transplant
tcell
respons
mhc
class
restrict
cell
mhc
class
ii
restrict
cell
thu
eff
ectiv
tcell
respons
need
match
genet
background
patient
tcell
transfer
develop
basi
promis
fi
nding
transfer
pathogenspecifi
c
tcell
clone
induc
clinic
signifi
cant
respons
sever
approach
use
obtain
pathogenspecifi
c
cell
antipathogenspecifi
c
cell
expand
ex
vivo
appropri
condit
usual
help
recombin
cytokin
synthet
peptid
cellular
compon
repres
pathogen
respond
cell
identifi
ed
product
remov
via
interferoncaptur
assay
transfer
patient
approach
requir
time
expans
cell
either
patient
mhcmatch
donor
protocol
enabl
expans
aspergillu
spp
candida
spp
term
respiratori
tract
pneumonia
infect
bacteria
viru
fungu
mycobacteria
also
combin
term
word
antibiot
antibiot
resist
treatment
drug
drug
develop
drug
pipelin
antibiot
develop
hostdirect
therapi
adjunct
therapi
steroid
immunotherapi
complement
search
public
us
center
diseas
control
prevent
http
clinicaltri
gov
googl
scholar
also
review
studi
cite
articl
identifi
ed
search
mucor
sppreactiv
cell
defi
ned
product
upon
reencount
nomin
target
antigen
cell
prolifer
increas
antifung
reactiv
phagocyt
new
antimicrobialresist
speci
bacteria
virus
fungi
continu
emerg
remark
genet
adapt
plastic
microbiota
respiratori
tract
infect
among
top
two
caus
death
global
microorgan
respect
intern
boundari
eas
travel
airborn
spread
make
threat
global
health
secur
increas
frequenc
antibiot
resist
limit
therapeut
option
emphasis
urgent
need
intern
cooper
tackl
new
emerg
microbi
threat
multidrugresist
microb
develop
new
therapeut
option
need
coupl
intern
regul
use
prescript
antimicrobi
drug
dsh
az
coordin
write
seri
paper
wrote
draft
outlin
subsequ
fi
nal
draft
author
contribut
relev
text
tabl
expert
section
section
contribut
fi
nalis
paper
fgh
serv
nonpaid
consult
multipl
compani
engag
market
andor
clinic
develop
antivir
respiratori
viral
infect
includ
sever
whose
therapeut
discuss
review
adama
biocryst
gsk
genentech
janssen
roch
romark
toyamamedivector
visterra
dwd
hold
founder
share
univers
manchest
spinout
compani
act
consult
triniti
group
biosystem
glaxosmithklin
sigma
tau
oxon
epidemiolog
consult
merck
astella
paid
give
talk
behalf
astella
gilead
pfi
zer
author
declar
confl
ict
interest
